Survival and dementia in GBA-associated Parkinson's disease: The mutation matters

Annals of Neurology

Volumn 80, Issue 5, 2016, Pages 662-673

  Cilia, Roberto ^a   Tunesi, Sara ^b,c   Marotta, Giorgio ^d   Cereda, Emanuele ^e   Siri, Chiara ^a   Tesei, Silvana ^a   Zecchinelli, Anna L ^a   Canesi, Margherita ^a   Mariani, Claudio B ^a   Meucci, Nicoletta ^a   Sacilotto, Giorgio ^a   Zini, Michela ^a   Barichella, Michela ^a   Magnani, Corrado ^b   Duga, Stefano ^f   Asselta, Rosanna ^f   Soldà, Giulia ^f   Seresini, Agostino ^d   Seia, Manuela ^d   Pezzoli, Gianni ^a   Goldwurm, Stefano ^a   more..

^a PARKINSON INSTITUTE   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f HUMANITAS UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE ETHYL ESTER TC 99M; DOPAMINE TRANSPORTER; GLUCOSYLCERAMIDASE; IOFLUPANE I 123; LEVODOPA;

ADULT; AGED; ARTICLE; BRAIN BLOOD FLOW; BRAIN PERFUSION; CATALEPSY; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; CORPUS STRIATUM; DAILY LIFE ACTIVITY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE DURATION; DISEASE SEVERITY; DORSOLATERAL PREFRONTAL CORTEX; DYSKINESIA; DYSPHAGIA; FEMALE; FOLLOW UP; GAIT; GENE MUTATION; GENETIC RISK; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOTE; HUMAN; IMAGE ANALYSIS; INTELLECTUAL IMPAIRMENT; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; MOTIVATION; MUTATIONAL ANALYSIS; NEUROIMAGING; ONSET AGE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SEX DIFFERENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPEECH; SURVIVAL; THOUGHT DISORDER; CROSS-SECTIONAL STUDY; DIAGNOSTIC IMAGING; GENETICS; MIDDLE AGED; MUTATION; PATHOPHYSIOLOGY; PROCEDURES; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; VERY ELDERLY;

AGE OF ONSET; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DEMENTIA; FEMALE; GLUCOSYLCERAMIDASE; HETEROZYGOTE; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84990249645     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24777     Document Type: Article

References (43)

1. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009;373:2055–2066.
2. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651–1661.
3. Schapira AH. Glucocerebrosidase and Parkinson disease: recent advances. Mol Cell Neurosci 2015;66:37–42.
4. Barkhuizen M, Anderson DG, Grobler AF. Advances in GBA-associated Parkinson's disease—pathology, presentation and therapies. Neurochem Int 2016;93:6–25.
5. Brockmann K, Srulijes K, Pflederer S, et al. GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord 2015;30:407–411.
6. Asselta R, Rimoldi V, Siri C, et al. Glucocerebrosidase mutations in primary parkinsonism. Parkinsonism Relat Disord 2014;20:1215–1220.
7. Beutler E, Gelbart T, Scott CR. Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis 2005;35:355–364.
8. Mata IF, Samii A, Schneer SH, et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol 2008;65:379–382.
9. Neumann J1, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009;132:1783–1794.
10. Gan-Or Z, Amshalom I, Kilarski LL, et al. Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology 2015;84:880–887.
11. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.
12. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57:1497–1499.
13. Levy G, Tang MX, Cote LJ, et al. Motor impairment in PD: relationship to incident dementia and age. Neurology 2000;55:539–444.
14. Cilia R, Cereda E, Klersy C, et al. Parkinson's disease beyond 20 years. J Neurol Neurosurg Psychiatry 2015;86:849–855.
15. Cereda E, Cilia R, Klersy C, et al. Dementia in Parkinson's disease: is male gender a risk factor? Parkinsonism Relat Disord 2016;26:67–72.
16. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863–1872.
17. Cilia R, Ko JH, Cho SS, et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiol Dis 2010;39:98–104.
18. Cilia R, Cho SS, van Eimeren T, et al. Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: a path modeling analysis. Mov Disord 2011;26:225–233.
19. Nobili F, Naseri M, De Carli F, et al. Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. Eur J Nucl Med Mol Imaging 2013;40:565–573.
20. Cilia R, Marotta G, Belletti A, et al. Reversible dopamine transporter reduction in drug-induced Parkinsonism. Mov Disord 2014;29:575–577.
21. Oishi N, Udaka F, Kameyama M, et al. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology 2005;65:1708–1715.
22. Macleod AD, Taylor KS, Counsell CE. Mortality in Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2014;29:1615–1622.
23. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005;20:1255–1263.
24. Brockmann K, Srulijes K, Hauser AK, et al. GBA-associated PD presents with nonmotor characteristics. Neurology 2011;77:276–280.
25. Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 2012;78:1434–1440.
26. Setó-Salvia N, Pagonabarraga J, Houlden H, et al. Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Mov Disord 2012;27:393–399.
27. Winder-Rhodes SE, Evans JR, Ban M, et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 2013;136:392–399.
28. Oeda T, Umemura A, Mori Y, et al. Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease. Neurobiol Aging 2015;36:3306–3313.
29. Mata IF, Leverenz JB, Weintraub D, et al. GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord. 2016;31:95–102.
30. Crosiers D, Verstraeten A, Wauters E, et al. Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort. Neurosci Lett 2016;629:160–164.
31. Gámez-Valero A, Prada-Dacasa P, Santos C, et al. GBA mutations are associated with earlier onset and male sex in dementia with Lewy bodies. Mov Disord 2016;31:1066–1070.
32. Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease. A prospective population-based long-term study. Neurology 2010;75:1270–1276.
33. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013;84:1258–1264.
34. Goker-Alpan O, Masdeu JC, Kohn PD, et al. The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. Brain 2012;135:2440–2448.
35. Lim SM, Katsifis A, Villemagne VL, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med 2009;50:1638–1645.
36. Wong K, Sidransky E, Verma A, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 2004;82:192–207.
37. Walker Z, Costa DC, Walker RW, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 2004;62:1568–1572.
38. Lesage S, Anheim M, Condroyer C, et al. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet 2011;20:202–210.
39. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011;146:37–52.
40. McNeill A, Magalhaes J, Shen C, et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 2014;137:1481–1495.
41. Ambrosi G, Ghezzi C, Zangaglia R, et al. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells. Neurobiol Dis 2015;82:235–242.
42. Alfonso P, Rodríguez-Rey JC, Gañán A, et al. Expression and functional characterization of mutated glucocerebrosidase alleles causing Gaucher disease in Spanish patients. Blood Cells Mol Dis 2004;32:218–225.
43. Malini E, Grossi S, Deganuto M, et al. Functional analysis of 11 novel GBA alleles. Eur J Hum Genet 2014;22:511–516.